Physician profile
Darin Usher
NPI 1689348336
$14,619.67
in general payments reported to CMS, 2019-2025
49 companies · $5,455 in 2025
The $5,455 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $21.26 · 2023: $3,419 · 2024: $5,503 · 2025: $5,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,259.23 |
| Education | $116.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,684.58 | 2021-2025 | |
| Ucb, INC. | $1,421.99 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Emd Serono, INC. | $1,340.82 | 2023-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $1,043.71 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $935.40 | 2023-2025 | |
| Celgene Corporation | $801.84 | 2023-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $698.46 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $480.66 | 2023-2025 | Ultomiris |
| Biogen, INC. | $441.32 | 2023-2025 | Vumerity, Tysabri, Tysabri |
| Argenx US, INC. | $434.35 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Pfizer INC. | $402.24 | 2023-2025 | |
| Amgen INC. | $374.34 | 2024-2025 | Uplizna |
| Sk Life Science, INC. | $337.92 | 2023-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $298.88 | 2023-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $295.26 | 2023-2025 | Vyepti, Rexulti |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $283.54 | 2021-2025 | Hyqvia, Gammagard |
| Amneal Pharmaceuticals LLC | $264.42 | 2023-2025 | Rytary, Ongentys, Neulasta |
| Axsome Therapeutics, INC. | $191.56 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $191.15 | 2023-2024 | Zeposia |
| Janssen Biotech, INC. | $184.93 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $169.77 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $148.67 | 2023-2024 | Emgality, Reyvow, Amyvid |
| Grifols USA, LLC | $146.13 | 2023-2025 | Gamunex-C |
| Genentech USA, INC. | $96.08 | 2023-2024 | Ocrevus, Enspryng |
| Banner Life Sciences, LLC | $91.29 | 2023-2024 | |
| Mdd US Operations, LLC | $84.75 | 2024-2025 | Gocovri, Apokyn |
| Jazz Pharmaceuticals INC. | $68.18 | 2024-2025 | |
| Impel Pharmaceuticals INC. | $63.21 | 2023 | Trudhesa |
| Acadia Pharmaceuticals INC | $60.38 | 2023-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $59.52 | 2023-2024 | Nuedexta |
| Sumitomo Pharma America, INC. | $56.53 | 2023 | Aptiom |
| Eisai INC. | $51.25 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $48.68 | 2024 | |
| Horizon Therapeutics Plc | $34.83 | 2023 | Uplizna |
| Neurelis, INC. | $33.49 | 2023-2024 | Valtoco |
| Cycle Pharmaceuticals INC | $31.60 | 2025 | Bafiertam, Tascenso Odt |
| Acorda Therapeutics, INC | $31.57 | 2023-2024 | Inbrija, Ampyra |
| Livanova USA, INC. | $29.69 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Merz Pharmaceuticals, LLC | $29.02 | 2025 | Inbrija, Xeomin |
| Redhill Biopharma INC. | $21.57 | 2021 | |
| Qol Medical, LLC | $21.51 | 2021 | |
| Boston Scientific Corporation | $21.49 | 2023 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $21.27 | 2023 | Qutenza |
| Braintree Laboratories, INC. | $19.23 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $19.22 | 2023 | Relyvrio |
| Tanabe Pharma America, INC. | $17.47 | 2025 | Radicava |
| Genzyme Corporation | $16.95 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.16 | 2021 | |
| Life Molecular Imaging LTD | $4.79 | 2025 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Usher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.